Cholesterol for Interference Testing Catalog # K2010008H Lot # Batch Dependent Expiration Batch Dependent Content Cholesterol 100 mg Appearance White powder Application Interference testing Shelf-Life 1 year Storage –20°C Keywords 3β-Hydroxy-5-cholestene, 5-Cholesten-3β-ol, cholesterol interference This high-purity cholesterol powder (100 mg) is formulated for interference testing in biochemical and clinical assay workflows. Supplied as a white powder and stable for up to one year when stored at –20°C, it enables researchers to simulate endogenous cholesterol interference in immunoassays, enzymatic reactions, and spectrophotometric platforms. The compound’s structural identity—3β-Hydroxy-5-cholestene—makes it ideal for evaluating lipid-related assay variability and matrix effects. Cholesterol is a known interferent in many diagnostic platforms, particularly those involving lipoproteins, steroid hormones, and membrane-bound receptors. This reagent allows for controlled spiking into specimens to assess assay robustness, specificity, and cross-reactivity. It is suitable for use in interference panels, method validation, and comparative studies across platforms. Researchers can use it to benchmark assay performance under physiologically relevant lipid concentrations and identify potential sources of analytical bias. Key benefits: High-purity cholesterol powder for interference testing Validated for use in immunoassays, enzymatic assays, and lipid profiling Stable for 1 year at –20°C; supplied in 100 mg aliquots Supports assay validation and cross-reactivity benchmarking Ideal for simulating endogenous cholesterol interference Indication for Use: This product is for Research Use Only (RUO). This product is not for administration to humans or animals. This product is not for human or veterinary diagnostic or therapeutic use. All Interference Products Brochure Download PDF References: Schiettecatte J, Anckaert E, Smitz J. Interferences in Immunoassays. Advances in Immunoassay Technology. 2012. Miller JJ, Levinson SS. Interferences In Immunoassays. Immunoassay. 1996;165–190. Ward G. Rational investigations of immunoassay interferences. Pathology. 2013;45. Park JY, Kricka LJ. Interferences in Immunoassay. The Immunoassay Handbook. 2013;403–416. EP07: Interference Testing in Clinical Chemistry. (2020). CLSI Gilles A et al. Targeting the Human 80S Ribosome in Cancer. Cells. 2020 Mar;9(3):E629. Coussens NP et al. Compound-Mediated Assay Interferences. Assay Guidance Manual. 2020 Feb. Wolff E et al. Overcoming cholesterol interference in tracer quantification. Rapid Commun Mass Spectrom. 2007;21(19):3175–9. Grafmeyer D et al. Bilirubin, haemolysis, turbidity effects on assays. Eur J Clin Chem Clin Biochem. 1995;33(1):31–52. Willeit J et al. Lipoprotein(a) and carotid artery disease. Stroke. 1995;26(9):1582–7.
